Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m. ET / 1:00 p.m. PT.
A live webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Following the webcast, a replay will be archived on the website for at least 30 days.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005829/en/
Xencor Inc. Aktie
Und die Aktie ist derzeit mit 16 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung ein Geheimtipp unserer Community.
Ein Kursziel von 31 € für Xencor Inc. würde eine Steigerung von mehr als 50% gegenüber dem aktuellen Kurs von 15.6 € bedeuten.